EA201391805A1 - Молекулярно-диагностический тест на рак - Google Patents

Молекулярно-диагностический тест на рак

Info

Publication number
EA201391805A1
EA201391805A1 EA201391805A EA201391805A EA201391805A1 EA 201391805 A1 EA201391805 A1 EA 201391805A1 EA 201391805 A EA201391805 A EA 201391805A EA 201391805 A EA201391805 A EA 201391805A EA 201391805 A1 EA201391805 A1 EA 201391805A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cancer
test
molecular diagnostic
treatment regimen
patients
Prior art date
Application number
EA201391805A
Other languages
English (en)
Other versions
EA025926B1 (ru
Inventor
Денис Пол Харкин
Фионнуала Паттерсон
Клэр Триндер
Имонн Дж. О'Брайен
Кэролайн Мичи
Чарли Гурли
Лора А. Хилл
Кэтрин Э. Китинг
Джуд О'Доннелл
Макс Бюлешо
Стив Деаро
Виталий Прутский
Ричард Кеннеди
Тимоти Дэвисон
Андреас Винтер
Эндрена Маккэйвиган
Original Assignee
Олмак Дайэгностикс Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Олмак Дайэгностикс Лимитед filed Critical Олмак Дайэгностикс Лимитед
Publication of EA201391805A1 publication Critical patent/EA201391805A1/ru
Publication of EA025926B1 publication Critical patent/EA025926B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7014—(Neo)vascularisation - Angiogenesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Предлагаются способы и композиции для идентификации молекулярно-диагностического теста на рак. Тест идентифицирует субтипы рака, восприимчивые к антиангиогенной терапии, и позволяет классифицировать пациентов в пределах этого субтипа. Изобретение может быть использовано для определения того, будут ли раковые пациенты клинически откликаться или не откликаться на схему лечения, до введения какого-либо антиангиогенного агента. Этот тест может быть использован при разных типах рака и с разными препаратами, которые прямо или косвенно влияют на ангиогенез или сигнальные пути ангиогенеза. В дополнение к этому, изобретение может быть использовано в качестве прогностического индикатора для определенных типов рака. В частности, изобретение касается использования определенных комбинаций прогностических маркеров, где экспрессия прогностических маркеров коррелирует с восприимчивостью или невосприимчивостью к схеме лечения.
EA201391805A 2011-06-02 2012-06-04 Молекулярно-диагностический тест на рак EA025926B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161492488P 2011-06-02 2011-06-02
PCT/US2012/040805 WO2012167278A1 (en) 2011-06-02 2012-06-04 Molecular diagnostic test for cancer

Publications (2)

Publication Number Publication Date
EA201391805A1 true EA201391805A1 (ru) 2014-03-31
EA025926B1 EA025926B1 (ru) 2017-02-28

Family

ID=47259970

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201691257A EA201691257A1 (ru) 2011-06-02 2012-06-04 Молекулярно-диагностический тест на рак
EA201391805A EA025926B1 (ru) 2011-06-02 2012-06-04 Молекулярно-диагностический тест на рак

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201691257A EA201691257A1 (ru) 2011-06-02 2012-06-04 Молекулярно-диагностический тест на рак

Country Status (13)

Country Link
US (1) US10260097B2 (ru)
EP (1) EP2715348B1 (ru)
JP (2) JP6067686B2 (ru)
KR (1) KR20140044341A (ru)
CN (1) CN103733065B (ru)
AU (1) AU2012261820B2 (ru)
BR (1) BR112013031019A2 (ru)
CA (1) CA2838086A1 (ru)
EA (2) EA201691257A1 (ru)
IL (1) IL229681A0 (ru)
MX (1) MX2013014065A (ru)
SG (2) SG10201604497UA (ru)
WO (1) WO2012167278A1 (ru)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201691257A1 (ru) 2011-06-02 2017-02-28 Олмак Дайэгностикс Лимитед Молекулярно-диагностический тест на рак
EP2667193A1 (en) * 2012-05-23 2013-11-27 Université d'Aix-Marseille MMP2 as a predictive biomarker of response to antiangiogenic therapy and survival after therapy in cancer patients
WO2014055398A1 (en) 2012-10-05 2014-04-10 Siemens Healthcare Diagnostics Inc. Method for detecting an increased risk or incidence of colorectal cancer
JP2015536667A (ja) * 2012-12-03 2015-12-24 アルマック・ダイアグノスティクス・リミテッドＡｌｍａｃ Ｄｉａｇｎｏｓｔｉｃｓ Ｌｉｍｉｔｅｄ 癌のための分子診断検査
GB201313342D0 (en) * 2013-07-26 2013-09-11 Cancer Rec Tech Ltd Biomarkers
US10617755B2 (en) 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
US10456470B2 (en) 2013-08-30 2019-10-29 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
GB201409479D0 (en) * 2014-05-28 2014-07-09 Almac Diagnostics Ltd Molecular diagnostic test for cancer
GB201409476D0 (en) * 2014-05-28 2014-07-09 Almac Diagnostics Ltd Molecular subtype for use in prognosis
GB201409478D0 (en) * 2014-05-28 2014-07-09 Almac Diagnostics Ltd Pro-angiogenic signature
JP2017523776A (ja) * 2014-07-14 2017-08-24 ジェネンテック， インコーポレイテッド 膠芽腫の診断方法及びその治療用組成物
WO2016133374A1 (ko) * 2015-02-17 2016-08-25 싸이퍼롬, 인코퍼레이티드 자궁수축억제제 부작용 방지를 위한 개인별 단백질 손상 정보 기반의 자궁수축억제제 선택 방법
CN105160208A (zh) * 2015-05-29 2015-12-16 杭州奥视图像技术有限公司 用于疾病亚型问题的基于网络的聚类方法
IL308735A (en) 2015-07-01 2024-01-01 Immatics Biotechnologies Gmbh New peptides and combinations of peptides used in immunotherapy against ovarian cancer and other types of cancer
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
US10650325B2 (en) * 2015-07-31 2020-05-12 Microsoft Technology Licensing, Llc Deterministic message distribution
CA2996426A1 (en) * 2015-10-05 2017-04-13 Cedars-Sinai Medical Center Method of classifying and diagnosing cancer
WO2017129537A1 (en) * 2016-01-25 2017-08-03 Sanofi Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer by measuring the level of a plasma biomarker
US20190127805A1 (en) * 2016-03-15 2019-05-02 Almac Diagnostics Limited Gene signatures for cancer detection and treatment
US11415584B2 (en) 2016-12-28 2022-08-16 Japanese Foundation For Cancer Research Biomarkers, test method, and test kit for predicting therapeutic effect of anti-VEGFR-2 antibody drug
CN107037210A (zh) * 2017-04-05 2017-08-11 北京蛋白质组研究中心 Thbs2蛋白检测物在制备肝细胞癌诊断试剂盒中的应用
WO2018213331A1 (en) * 2017-05-16 2018-11-22 Lankenau Institute For Medical Research Compositions comprising ligands to rhob protein and the uses thereof
WO2018231771A1 (en) * 2017-06-13 2018-12-20 Bostongene Corporation Systems and methods for generating, visualizing and classifying molecular functional profiles
US20180365372A1 (en) * 2017-06-19 2018-12-20 Jungla Inc. Systems and Methods for the Interpretation of Genetic and Genomic Variants via an Integrated Computational and Experimental Deep Mutational Learning Framework
EP3461915A1 (en) 2017-10-02 2019-04-03 Koninklijke Philips N.V. Assessment of jak-stat1/2 cellular signaling pathway activity using mathematical modelling of target gene expression
EP3502279A1 (en) 2017-12-20 2019-06-26 Koninklijke Philips N.V. Assessment of mapk-ap 1 cellular signaling pathway activity using mathematical modelling of target gene expression
WO2019165366A1 (en) * 2018-02-23 2019-08-29 Beth Israel Deaconess Medical Center Drug efficacy evaluations
CA3095056A1 (en) * 2018-04-13 2019-10-17 Freenome Holdings, Inc. Machine learning implementation for multi-analyte assay of biological samples
TWI815137B (zh) 2018-06-15 2023-09-11 漢達生技醫藥股份有限公司 尼洛替尼十二烷基硫酸鹽之結晶
CA3107571A1 (en) * 2018-06-27 2020-01-02 Qcdx Llc Biological sample holder and handler
CN109585011A (zh) * 2018-10-26 2019-04-05 朱海燕 胸痛患者的病症诊断方法及机器可读存储介质
EP3880848A4 (en) * 2018-11-14 2022-07-27 Beyondspring Pharmaceuticals, Inc. CANCER TREATMENT METHODS USING TUBULIN-BINDING AGENTS
WO2021016402A1 (en) * 2019-07-22 2021-01-28 Mission Bio, Inc. Using machine learning to optimize assays for single cell targeted dna sequencing
KR102289533B1 (ko) * 2019-08-19 2021-08-17 주식회사 테라젠바이오 특정 약물의 타겟 유전자와 관련된 시그니처를 기초로 타겟 유전자와 관련된 유전자들을 판단하는 전자 장치, 방법 및 상기 방법을 실행하기 위한 컴퓨터 프로그램
CN112489800B (zh) * 2020-12-03 2024-05-28 安徽医科大学第一附属医院 一种***癌患者的预后评估***及其应用
CN116312814A (zh) * 2021-12-02 2023-06-23 复旦大学 一种肺腺癌分子分型模型的构建方法、设备、装置以及试剂盒
CN116863995B (zh) * 2023-08-29 2024-05-14 北京大学第一医院 Alpk2，itga11，esyt1，cdh17在预测药物出血中的应用

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525464A (en) 1987-04-01 1996-06-11 Hyseq, Inc. Method of sequencing by hybridization of oligonucleotide probes
US5202231A (en) 1987-04-01 1993-04-13 Drmanac Radoje T Method of sequencing of genomes by hybridization of oligonucleotide probes
GB8810400D0 (en) 1988-05-03 1988-06-08 Southern E Analysing polynucleotide sequences
US5547839A (en) 1989-06-07 1996-08-20 Affymax Technologies N.V. Sequencing of surface immobilized polymers utilizing microflourescence detection
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
EP0430881A3 (en) 1989-11-29 1991-10-23 Ciba-Geigy Ag Photochromic compounds, process for their preparation and their use
US5288644A (en) 1990-04-04 1994-02-22 The Rockefeller University Instrument and method for the sequencing of genome
US5324633A (en) 1991-11-22 1994-06-28 Affymax Technologies N.V. Method and apparatus for measuring binding affinity
DE69322266T2 (de) 1992-04-03 1999-06-02 Perkin Elmer Corp Proben zusammensetzung und verfahren
US5503980A (en) 1992-11-06 1996-04-02 Trustees Of Boston University Positional sequencing by hybridization
US5858659A (en) 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
US5470710A (en) 1993-10-22 1995-11-28 University Of Utah Automated hybridization/imaging device for fluorescent multiplex DNA sequencing
GB9401833D0 (en) 1994-02-01 1994-03-30 Isis Innovation Method for discovering ligands
WO1997027317A1 (en) 1996-01-23 1997-07-31 Affymetrix, Inc. Nucleic acid analysis techniques
US6946442B2 (en) 1994-11-30 2005-09-20 Asif Syed Ahmed Method of hastening cervical ripening
GB9507238D0 (en) 1995-04-07 1995-05-31 Isis Innovation Detecting dna sequence variations
US5661028A (en) 1995-09-29 1997-08-26 Lockheed Martin Energy Systems, Inc. Large scale DNA microsequencing device
US6680175B2 (en) * 1998-05-05 2004-01-20 Adherex Technologies, Inc. Methods for diagnosing and evaluating cancer
WO2004005883A2 (en) 2002-07-02 2004-01-15 The Johns Hopkins University Secreted and cytoplasmic tumor endothelial markers
US6998234B2 (en) 2000-11-03 2006-02-14 Oncotech, Inc. Methods for cancer prognosis and diagnosis relating to tumor vascular endothelial cells
US20030215424A1 (en) 2002-05-15 2003-11-20 Seul Kyung Hwan Method of modulating angiogenesis
RS20150135A1 (en) * 2003-05-30 2015-08-31 Genentech Inc. TREATMENT WITH ANTI-VEGF ANTIBODIES
US7659062B2 (en) 2003-06-03 2010-02-09 The Board of Trustee of the University of Arkansas System Gene expression profiling of uterine serous papillary carcinomas and ovarian serous papillary tumors
WO2005066371A2 (en) 2003-12-31 2005-07-21 The Penn State Research Foundation Methods for predicting and overcoming resistance to chemotherapy in ovarian cancer and for predicting colon cancer occurrence
US20080113874A1 (en) * 2004-01-23 2008-05-15 The Regents Of The University Of Colorado Gefitinib sensitivity-related gene expression and products and methods related thereto
ES2550614T3 (es) 2004-04-09 2015-11-11 Genomic Health, Inc. Marcadores de expresión génica para predecir la respuesta a la quimioterapia
RU2006144122A (ru) * 2004-05-14 2008-06-20 Лудуиг Инститьют Фор Кэнсе Рисеч (Us) Идентификация и характеризация субпопуляции глиобластом, чувствительных к лечению иматинибом
AU2005263972A1 (en) * 2004-07-23 2006-01-26 Astrazeneca Ab Method of predicting the responsiveness of a tumor to erbB receptor drugs
US20060134663A1 (en) 2004-11-03 2006-06-22 Paul Harkin Transcriptome microarray technology and methods of using the same
US7862995B2 (en) 2004-12-10 2011-01-04 Targeted Molecular Diagnostics Methods and materials for predicting responsiveness to treatment with dual tyrosine kinase inhibitor
ATE477495T1 (de) * 2005-03-16 2010-08-15 Osi Pharm Inc Biologische marker prediktiv für das ansprechen von krebs auf inhibitoren der kinase des rezeptors für epidermalen wachstumsfaktor
US20080305962A1 (en) * 2005-07-29 2008-12-11 Ralph Markus Wirtz Methods and Kits for the Prediction of Therapeutic Success, Recurrence Free and Overall Survival in Cancer Therapies
ES2374450T3 (es) * 2005-09-20 2012-02-16 OSI Pharmaceuticals, LLC Marcadores biológicos predictivos de respuesta anticancerígena para inhibidores de cinasa del receptor del factor de crecimiento 1 similar a insulina.
US8445198B2 (en) * 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
EP1963862A4 (en) * 2005-12-05 2010-03-03 Merck & Co Inc METHODS FOR PREDICTING REACTION TO TREATMENT FROM EXPRESSION PROFILES OF PROTEIN AND TRANSCRIPTIONAL BIOMARKERS
WO2007067500A2 (en) 2005-12-05 2007-06-14 Genomic Health, Inc. Predictors of patient response to treatment with egfr inhibitors
KR20080094803A (ko) 2006-01-27 2008-10-24 트리패스 이미징, 인코포레이티드 난소암의 발병 가능성이 높은 환자를 확인하는 방법 및 그의 조성물
US20090275633A1 (en) * 2006-04-13 2009-11-05 Oncomethylome Sciences Sa Novel Tumour Suppressor
US8768629B2 (en) * 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
CA2662508A1 (en) 2006-09-19 2008-07-10 Novartis Ag Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors
EP2201142A1 (en) * 2007-08-13 2010-06-30 Almac Diagnostics Limited A 3' -based sequencing approach for microarray manufacture
US20090092603A1 (en) 2007-09-25 2009-04-09 Bamdad Cynthia C Early diagnosis and treatment of drug resistance in muc1-positive cancer
NZ562237A (en) 2007-10-05 2011-02-25 Pacific Edge Biotechnology Ltd Proliferation signature and prognosis for gastrointestinal cancer
BRPI0817158A2 (pt) * 2007-11-09 2015-04-14 Genentech Inc "método de identificar um paciente com câncer renal, kit, métodos e conjunto de compostos"
CA2707900A1 (en) 2007-12-07 2009-06-18 Oregon Health & Science University Methods to determine if a subject will respond to a bcr-abl inhibitor
US8114593B2 (en) 2008-03-12 2012-02-14 University Of Medicine And Dentistry Of New Jersey Cancer biomarker genes and gene products and methods for using the same
CA2726426A1 (en) * 2008-06-04 2009-12-10 The Arizona Board Of Regents, On Behalf Of The University Of Arizona Diffuse large b-cell lymphoma markers and uses therefor
CA2726811C (en) * 2008-06-06 2019-11-26 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Survival predictor for diffuse large b cell lymphoma
EP2318543A2 (en) * 2008-07-16 2011-05-11 Dana-Farber Cancer Institute Inc. Signatures and pcdeterminants associated with prostate cancer and methods of use thereof
JP5606438B2 (ja) 2008-07-23 2014-10-15 エフ．ホフマン−ラ ロシュ アーゲー 抗血管新生療法を受容可能な被験体の同定
EA020764B1 (ru) 2008-12-23 2015-01-30 Мерк Патент Гмбх Биомаркеры для ингибиторов с антиангиогенной активностью
WO2010088688A2 (en) * 2009-02-02 2010-08-05 Biotheranostics, Inc. Diagnosis of in situ and invasive breast cancer
SG175832A1 (en) 2009-05-01 2011-12-29 Genomic Health Inc Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer and response to chemotherapy
US7615353B1 (en) * 2009-07-06 2009-11-10 Aveo Pharmaceuticals, Inc. Tivozanib response prediction
ES2530732T3 (es) * 2009-09-17 2015-03-05 Hoffmann La Roche Procedimientos de diagnóstico para el cáncer de pulmón
CA2811015A1 (en) 2010-09-15 2012-03-22 Almac Diagnostics Limited Molecular diagnostic test for cancer
WO2012052757A1 (en) * 2010-10-20 2012-04-26 Astrazeneca Ab Tumour phenotype patient selection method
EP2659005A4 (en) 2010-12-28 2016-08-24 Caris Mpi Inc MOLECULAR PROFILING OF CANCER
EA201691257A1 (ru) 2011-06-02 2017-02-28 Олмак Дайэгностикс Лимитед Молекулярно-диагностический тест на рак
SG11201403927XA (en) 2012-01-13 2014-08-28 Genentech Inc Biological markers for identifying patients for treatment with vegf antagonists
EP2667193A1 (en) 2012-05-23 2013-11-27 Université d'Aix-Marseille MMP2 as a predictive biomarker of response to antiangiogenic therapy and survival after therapy in cancer patients
JP2015536667A (ja) 2012-12-03 2015-12-24 アルマック・ダイアグノスティクス・リミテッドＡｌｍａｃ Ｄｉａｇｎｏｓｔｉｃｓ Ｌｉｍｉｔｅｄ 癌のための分子診断検査

Also Published As

Publication number Publication date
CN103733065A (zh) 2014-04-16
EP2715348A1 (en) 2014-04-09
EP2715348A4 (en) 2015-10-07
JP6067686B2 (ja) 2017-01-25
SG195208A1 (en) 2013-12-30
BR112013031019A2 (pt) 2017-03-21
JP2014516552A (ja) 2014-07-17
IL229681A0 (en) 2014-01-30
CA2838086A1 (en) 2012-12-06
MX2013014065A (es) 2014-06-23
US10260097B2 (en) 2019-04-16
WO2012167278A1 (en) 2012-12-06
NZ618191A (en) 2015-04-24
CN103733065B (zh) 2017-12-15
JP2017079772A (ja) 2017-05-18
KR20140044341A (ko) 2014-04-14
EA025926B1 (ru) 2017-02-28
AU2012261820B2 (en) 2017-01-19
SG10201604497UA (en) 2016-07-28
US20140342924A1 (en) 2014-11-20
EP2715348B1 (en) 2019-04-10
EA201691257A1 (ru) 2017-02-28

Similar Documents

Publication Publication Date Title
EA201391805A1 (ru) Молекулярно-диагностический тест на рак
MX2015006955A (es) Prueba de diagnostico molecular para cancer.
MX2016003016A (es) Pruebas diagnosticas moleculares para cancer pulmonar.
EA201390370A1 (ru) Молекулярно-диагностический тест для определения онкологического заболевания
MX356802B (es) Marcadores biologicos para identificar pacientes para tratamiento con antagonistas de vegf.
MX2016002423A (es) Composiciones y metodos de diagnostico para el tratamiento de glioblastoma.
MX2016003077A (es) Prueba diagnostica molecular para cancer esofagico.
BR112014024219A8 (pt) Métodos de determinação, de otimização da eficácia terapêutica, de monitoramento, de seleção de terapia e de diagnóstico de distúrbio e kit
TN2013000358A1 (en) Fgfr and ligands thereof as biomarkers for breast cancer in hr positive subjects
BR112015029318A2 (pt) marcadores específicos de caminhos para diagnóstico da síndrome do intestino irritável
WO2012006589A3 (en) Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
MX2020005165A (es) Biogenesis de miarn en exosomas para diagnostico y terapia.
MX2017008421A (es) Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga.
CO7240393A2 (es) Composiciones que comprenden un aptámero anti-factor de crecimiento derivado de plaquetas (anti-pdgf) y un antagonista del factor de crecimiento endotelial vascular (vegf)
BR112014015105A2 (pt) inibidores da via de sinalização notch e uso do mesmo no tratamento de cânceres
MX2013002084A (es) Biomarcadores y metodos de tratamiento.
BR112019009256A2 (pt) métodos para tratar síndrome de alport usando bardoxolona metil ou análogos do mesmo
PH12015500252A1 (en) Niclosamide for the treatment of solid tumors
GT201300235A (es) Uso de 2,3-dihidroimidazo (1,2-c) quinazolinas sustituidas
DK2900279T3 (da) Grpr-antagonister til detektering, diagnose og behandling af grpr-positiv cancer
MX2017006242A (es) Determinacion de niveles de glicosaminoglicanos mediante espectrometria de masas.
BR112015017241A2 (pt) doadores de nitroxil com índice terapêutico melhorado
BR112015020054A2 (pt) Método de detectar resistência aos efeitos terapêuticos de um inibidor de akt em uma célula cancerosa
IN2014KN00742A (ru)
CR20130402A (es) Unidad de interfaz y sistema de medición

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU